CD274 and neoplasm: Biomarkers such as PD-L1 combined positive score, PD-L1 tumor proportion score, microsatellite instability, tumor mutation burden, and immune signatures are proposed to predict immunotherapy efficacy, but consensus is lacking, and their use in chemotherapy and radiotherapy is underexplored.